| Insurers Press for Tighter Oversight Insurance-industry executives are urging state regulators to thwart what they call widening efforts by professional investors to use various consumer products to turn a profit. online.wsj.com |
Clearing it Up: Getting Real with Your Teen About Acne. - Video During June National Acne Awareness Month, Experts Advise Parents to Help Teens Focus on Health and Well-Being, Limit Summertime Stress and Get on Track with Proper Skin-Care Regimen feedproxy.google.com |
Protecting your skin from sun damage - Video An Industry-First Campaign to Educate Tour Players & Fans on Prevention and Treatment of Sun Damage Including Fraxel’s re:store Laser Technology feedproxy.google.com |
Why I Bought ImmunoGen After the Plunge Marco G. submits:ImmunoGen (IMGN) is a Waltham, Massachusetts based biotechnology company. On Friday August 27th, 2010, their collaborative partner Genetech, a member of the Roche Group, received a Refuse to File (RTF) letter from the US Food and Drug Administration (FDA) for the accelerated approval of the Bilogic License Application (BLA) for trastuzumab-DM1. IMGN stock plunged from $8.40 the day before to $5.90 premarket. At the end of the day the stock rested at $5.16; see the chart following for the plunge. Complete Story » seekingalpha.com |
Acorda Hopes to Meet Huge Need in Challenging Stroke Market Douglas Cress submits:By vandersonTime is critical when a patient suffers from a stroke. Approximately 87 percent of strokes are caused by blood clots blocking blood flow to the brain, a condition known as ischemic stroke. The drug tPA can restore normal blood flow, but physicians only have a brief window of opportunity—just a few hours from the first symptom—to treat the patient. Furthermore, only 3 to 5 percent of patients are eligible for this treatment option. According to a recent USA Today article, only about a third of stroke sufferers reach the hospital in time for testing to determine their eligibility for tPA therapy. In the United States, stroke affects approximately 800,000 people each year. It is the third leading cause of death as well as the leading cause of disability in the U.S. In many cases, the patient survives but suffers permanent disability or neurological damage. The American Stroke Association estimates that Americans will pay about $73.7 billion in 2010 for stroke-related medical costs and disability. The clinical need is clear: Patients who suffer an ischemic stroke but do not reach the hospital in time to qualify for tPA therapy desperately need a pharmacological alternative. Complete Story » seekingalpha.com |